• News
  • BioTech

Cardium warned about market listing

Cardium Therapeutics (NYSE: CXM), a once high-flying biotech firm in Sorrento Valley, has until Dec. 31 to rebuild its stockholders’ equity or it may face suspension or removal from the New York Stock Exchange’s MKT board -- formerly the American Stock Exchange.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!